Tramper-Stranders Gerdien A, van der Ent Cornelis K, Gerritsen Susan A M, Fleer André, Kimpen Jan L L, Wolfs Tom F W
Department of Paediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Centre Utrecht, The Netherlands.
J Antimicrob Chemother. 2007 Sep;60(3):665-8. doi: 10.1093/jac/dkm235. Epub 2007 Jun 29.
Patients with cystic fibrosis (CF) are frequently colonized by macrolide-resistant Staphylococcus aureus, a result of maintenance macrolide therapy. As transmission of S. aureus between household contacts is common, we examined the prevalence of macrolide-resistant S. aureus colonization in CF patients on maintenance azithromycin therapy and their household contacts and compared this with the S. aureus macrolide resistance prevalence in the community.
Sixty-five CF patients on maintenance macrolide therapy and 194 household contacts were screened for S. aureus colonization by culturing sputa, cough swabs and nasal swabs. Resistance to macrolide, lincosamide and methicillin was determined by disc diffusion tests. The prevalence of macrolide-resistant S. aureus colonization in both groups was compared with figures from a nationwide study into S. aureus carriership and resistance. To assess possible transmission, genotyping of S. aureus was performed using the spa-typing method.
Macrolide resistance among CF patients with S. aureus colonization was 69.6%; 75% of these isolates displayed lincosamide resistance too. Among household contacts, macrolide resistance prevalence did not differ significantly from resistance prevalence in the community (9.6% versus 6.3%; P = 0.358). No methicillin resistance was observed. No identical (macrolide-resistant and -susceptible) S. aureus genotypes were observed between CF patients and their household contacts except for one household, suggesting a probable transmission.
No significant increase in macrolide-resistant S. aureus colonization was observed among household contacts of CF patients on long-term azithromycin therapy. Transmission of macrolide-resistant S. aureus could not be proved by genotyping in the majority of households.
由于长期使用大环内酯类药物治疗,囊性纤维化(CF)患者常被耐大环内酯类金黄色葡萄球菌定植。鉴于金黄色葡萄球菌在家庭接触者之间的传播很常见,我们调查了接受维持性阿奇霉素治疗的CF患者及其家庭接触者中耐大环内酯类金黄色葡萄球菌定植的患病率,并将其与社区中金黄色葡萄球菌大环内酯类耐药率进行比较。
通过对痰液、咳嗽拭子和鼻拭子进行培养,对65例接受维持性大环内酯类治疗的CF患者和194名家庭接触者进行金黄色葡萄球菌定植筛查。通过纸片扩散试验测定对大环内酯类、林可酰胺类和甲氧西林的耐药性。将两组中耐大环内酯类金黄色葡萄球菌定植的患病率与一项全国性金黄色葡萄球菌携带情况和耐药性研究的数据进行比较。为评估可能的传播情况,采用spa分型法对金黄色葡萄球菌进行基因分型。
金黄色葡萄球菌定植的CF患者中,大环内酯类耐药率为69.6%;其中75%的分离株也显示对林可酰胺类耐药。在家庭接触者中,大环内酯类耐药率与社区耐药率无显著差异(9.6%对6.3%;P = 0.358)。未观察到耐甲氧西林情况。除一个家庭外,CF患者与其家庭接触者之间未观察到相同的(耐大环内酯类和敏感)金黄色葡萄球菌基因型,提示可能存在传播。
在接受长期阿奇霉素治疗的CF患者的家庭接触者中,未观察到耐大环内酯类金黄色葡萄球菌定植显著增加。在大多数家庭中,通过基因分型无法证实耐大环内酯类金黄色葡萄球菌的传播。